CD47-SIRPα 免疫检查点。
The CD47-SIRPα Immune Checkpoint.
机构信息
Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Department of Medical Oncology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.
出版信息
Immunity. 2020 May 19;52(5):742-752. doi: 10.1016/j.immuni.2020.04.011.
Abstract
The cytotoxic activity of myeloid cells is regulated by a balance of signals that are transmitted through inhibitory and activating receptors. The Cluster of Differentiation 47 (CD47) protein, expressed on both healthy and cancer cells, plays a pivotal role in this balance by delivering a "don't eat me signal" upon binding to the Signal-regulatory protein alpha (SIRPα) receptor on myeloid cells. Here, we review the current understanding of the role of the CD47-SIRPα axis in physiological tissue homeostasis and as a promising therapeutic target in, among others, oncology, fibrotic diseases, atherosclerosis, and stem cell therapies. We discuss gaps in understanding and highlight where additional insight will be beneficial to allow optimal exploitation of this myeloid cell checkpoint as a target in human disease.
摘要
髓系细胞的细胞毒性活性受通过抑制性和激活性受体传递的信号的平衡调节。分化簇 47（CD47）蛋白在健康细胞和癌细胞上均表达，通过与髓系细胞上的信号调节蛋白 alpha（SIRPα）受体结合传递“不要吃我信号”，在这种平衡中发挥关键作用。在这里，我们回顾了 CD47-SIRPα 轴在生理组织稳态中的作用及其作为一种有前途的治疗靶点的作用，特别是在肿瘤学、纤维化疾病、动脉粥样硬化和干细胞治疗中。我们讨论了理解上的差距，并强调了需要额外的见解将如何有益于将这种髓系细胞检查点作为人类疾病的靶点进行最佳利用。
相似文献
1
The CD47-SIRPα Immune Checkpoint.CD47-SIRPα 免疫检查点。
Immunity. 2020 May 19;52(5):742-752. doi: 10.1016/j.immuni.2020.04.011.
2
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.CD47-SIRPα信号轴作为癌症中的一种固有免疫检查点。
Immunol Rev. 2017 Mar;276(1):145-164. doi: 10.1111/imr.12527.
3
Cancer immunotherapy targeting the CD47/SIRPα axis.靶向CD47/SIRPα轴的癌症免疫疗法。
Eur J Cancer. 2017 May;76:100-109. doi: 10.1016/j.ejca.2017.02.013. Epub 2017 Mar 10.
4
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.SIRPα-CD47 免疫检查点阻断在癌症治疗中的应用。
Trends Immunol. 2018 Mar;39(3):173-184. doi: 10.1016/j.it.2017.12.005. Epub 2018 Jan 11.
5
Deciphering the role of CD47 in cancer immunotherapy.解析 CD47 在癌症免疫疗法中的作用。
J Adv Res. 2024 Sep;63:129-158. doi: 10.1016/j.jare.2023.10.009. Epub 2023 Oct 28.
6
Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.胃癌的新型免疫疗法：靶向CD47-SIRPα轴。
Cancer Metastasis Rev. 2025 May 29;44(2):52. doi: 10.1007/s10555-025-10269-z.
7
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.靶向髓系检查点受体 SIRPα 可增强先天和适应性免疫反应，从而促进抗肿瘤活性。
J Hematol Oncol. 2020 Nov 30;13(1):160. doi: 10.1186/s13045-020-00989-w.
8
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.CD47-SIRPα 免疫检查点在肿瘤免疫逃逸和固有免疫治疗中的作用。
Life Sci. 2021 May 15;273:119150. doi: 10.1016/j.lfs.2021.119150. Epub 2021 Mar 1.
9
Is CD47 an innate immune checkpoint for tumor evasion?CD47是肿瘤逃逸的固有免疫检查点吗？
J Hematol Oncol. 2017 Jan 11;10(1):12. doi: 10.1186/s13045-016-0381-z.
10
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.用 Fc 功能下调的抗 CD47 治疗性抗体调节 CD47-SIRPα 固有免疫检查点轴。
Cancer Immunol Immunother. 2022 Feb;71(2):473-489. doi: 10.1007/s00262-021-03010-6. Epub 2021 Jul 10.
引用本文的文献
1
Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors.将免疫疗法扩展至CAR-T细胞之外：改造多种免疫细胞以靶向实体瘤
Cancers (Basel). 2025 Sep 5;17(17):2917. doi: 10.3390/cancers17172917.
2
Synergistic Ferroptosis-Immunotherapy Nanoplatforms: Multidimensional Engineering for Tumor Microenvironment Remodeling and Therapeutic Optimization.协同铁死亡-免疫疗法纳米平台：用于肿瘤微环境重塑和治疗优化的多维工程
Nanomicro Lett. 2025 Sep 2;18(1):56. doi: 10.1007/s40820-025-01862-6.
3
Inhibition of Extracellular Matrix Protein Fibulin-3 Reduces Immunosuppressive Signaling and Increases Macrophage Activation in Glioblastoma.抑制细胞外基质蛋白Fibulin-3可减少免疫抑制信号并增强胶质母细胞瘤中的巨噬细胞活化。
Cancer Res Commun. 2025 Sep 1;5(9):1599-1610. doi: 10.1158/2767-9764.CRC-25-0083.
4
Roles of the phagocytosis checkpoint in radiotherapy.吞噬作用检查点在放射治疗中的作用。
Cell Death Dis. 2025 Aug 20;16(1):630. doi: 10.1038/s41419-025-07921-5.
5
Deciphering the role of in liver diseases: Mechanisms, clinical relevance, and emerging therapeutic opportunities.解读[具体物质或因素]在肝脏疾病中的作用：机制、临床相关性及新出现的治疗机会。 （注：原文中“of”后面缺少具体内容）
World J Hepatol. 2025 Jul 27;17(7):106795. doi: 10.4254/wjh.v17.i7.106795.
6
The potential of efferocytosis for the treatment of bronchial asthma: A review of current trends, mechanisms and prospects.吞噬作用在支气管哮喘治疗中的潜力：当前趋势、机制及前景综述
Biochem Biophys Rep. 2025 Jul 19;43:102161. doi: 10.1016/j.bbrep.2025.102161. eCollection 2025 Sep.
7
Immunopharmacology of senescence: targeting the senescence-associated secretory phenotype (SASP)-a mechanism-based review.衰老的免疫药理学：靶向衰老相关分泌表型（SASP）——基于机制的综述
Inflammopharmacology. 2025 Aug;33(8):4291-4310. doi: 10.1007/s10787-025-01867-y. Epub 2025 Jul 26.
8
The USP1-WDR48 deubiquitinase complex functions as a molecular switch regulating tumor-associated macrophage activation and anti-tumor response.USP1-WDR48去泛素化酶复合物作为一种分子开关，调节肿瘤相关巨噬细胞的激活和抗肿瘤反应。
Cell Death Differ. 2025 Jul 24. doi: 10.1038/s41418-025-01548-x.
9
Targeting CD37 promotes macrophage-dependent phagocytosis of multiple cancer cell types and facilitates tumor clearance in mice.靶向CD37可促进巨噬细胞对多种癌细胞类型的吞噬作用，并有助于清除小鼠体内的肿瘤。
Nat Commun. 2025 Jul 18;16(1):6610. doi: 10.1038/s41467-025-61348-2.
10
Enhancement of activation-induced T cell proliferation by SIRPG in a CD47-independent manner.SIRPG以不依赖CD47的方式增强激活诱导的T细胞增殖。
bioRxiv. 2025 May 7:2025.05.01.651731. doi: 10.1101/2025.05.01.651731.
本文引用的文献
1
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.髓系恶性肿瘤中巨噬细胞免疫检查点CD47的治疗靶向作用
Front Oncol. 2020 Jan 22;9:1380. doi: 10.3389/fonc.2019.01380. eCollection 2019.
2
Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.用缺乏 CD47 的肿瘤细胞进行免疫接种可在小鼠中引发抗肿瘤免疫反应。
Nat Commun. 2020 Jan 29;11(1):581. doi: 10.1038/s41467-019-14102-4.
3
Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential.新型 CD47 纳米抗体的临床前开发，具有更低的毒性和增强的抗癌治疗潜力。
J Nanobiotechnology. 2020 Jan 13;18(1):12. doi: 10.1186/s12951-020-0571-2.
4
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.靶向敲除髓系细胞中的 PD-1 可诱导抗肿瘤免疫。
Sci Immunol. 2020 Jan 3;5(43). doi: 10.1126/sciimmunol.aay1863.
5
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.ADU-1805 是一种选择性的全等位基因抗 SIRPα 抗体，可阻断 SIRPα-CD47 固有免疫检查点，对其功能进行了鉴定。
J Immunother Cancer. 2019 Dec 4;7(1):340. doi: 10.1186/s40425-019-0772-0.
6
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.Probody疗法：一类新兴的疗法，旨在增强靶向效应，同时降低肿瘤外毒性，用于免疫肿瘤学。
Clin Cancer Res. 2020 Mar 1;26(5):984-989. doi: 10.1158/1078-0432.CCR-19-1457. Epub 2019 Oct 10.
7
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.CD24 通过巨噬细胞 Siglec-10 的信号传导是癌症免疫治疗的一个靶点。
Nature. 2019 Aug;572(7769):392-396. doi: 10.1038/s41586-019-1456-0. Epub 2019 Jul 31.
8
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.发现针对髓系检查点受体 SIRPα 的高亲和力、全等位基因和全哺乳动物反应性抗体。
MAbs. 2019 Aug/Sep;11(6):1036-1052. doi: 10.1080/19420862.2019.1624123. Epub 2019 Jul 1.
9
Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.抗体调理可实现 MHC 错配造血干细胞移植和器官移植物耐受。
Cell Stem Cell. 2019 Aug 1;25(2):185-192.e3. doi: 10.1016/j.stem.2019.05.018. Epub 2019 Jun 13.
10
Targeting CD47 in Sézary syndrome with SIRPαFc.靶向 Sézary 综合征中的 CD47 用 SIRPαFc。
Blood Adv. 2019 Apr 9;3(7):1145-1153. doi: 10.1182/bloodadvances.2018030577.
Zotero 插件